Stop Acting So Surprised That the Dow Just Hit 23,000
Logging record highs is par for the course over the Dow's 121-year history.
3 Reasons the Best Is Yet to Come for Netflix Investors
Growing through a rate hike, paid international subscribers surpassing domestic accounts, and the leverage behind the rate hike should keep the good times going for Netflix stock.
5 Oil Stocks Built to Thrive at $50 Crude
Crude has crept back above $50 a barrel in recent weeks, which is a boon for these oil stocks.
Find out what the tobacco giant's third-quarter results signaled for its future.
Time to elect your workplace benefits for the upcoming year? Here's what you need to know.
The more sensors, the merrier?
These two stocks probably didn't show up on your last dividend screen, but overlooking them could be a huge mistake.
History suggests cryptocurrencies are likely in a bubble.
NVIDIA is now a heavyweight in the technology sector. Will it get knocked out, or keep punching?
Solar and energy storage could become a great solution for commercial buildings if a few roadblocks hindering adoption come down.
With retirees living longer than ever, these value stocks offer an opportunity to really grow your nest egg.
Relax. Your aren't being manipulated.
Wells Fargo's latest earnings show that the bank is still plagued by its fake-accounts scandal.
Two tech stocks and one biotech stock rank near the top of the list for billionaire investors.
Past performance isn't always a predictor of future results. But it could be sometimes.
When you hit 60, your investing goals change considerably, which is why you'll want to consider these two high yielders.
Why very low nicotine and very high stock returns go hand in hand.
New data reveals that the typical American could be making $7,500 more each year. Here's how to snag that much-needed cash.
Three stocks that, for different reasons, look very cheap today. But cheap isn't the same as being worth buying. Keep reading to find out if these are worth buying.
These top stocks may define set-it and forget-it investing.
If you're on the hunt for small-cap biotechs that could be big winners next year, Amarin, MannKind Corp., and 22nd Century Group need to be on your radar right now.
Not having a traditional job comes with big perks, as well as significant downside.
United Continental's Q3 earnings beat analysts' expectations, but that was a small victory considering that adjusted EPS fell 29% year over year.